

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
19 June 2025 (19.06.2025)



(10) International Publication Number  
**WO 2025/124364 A1**

(51) International Patent Classification:

*C12N 15/113* (2010.01) *A61P 35/00* (2006.01)  
*A61K 31/713* (2006.01) *A61P 35/04* (2006.01)  
*A61P 3/06* (2006.01) *A61P 9/00* (2006.01)

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,  
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,  
ZA, ZM, ZW.

(21) International Application Number:

PCT/CN2024/137988

(22) International Filing Date:

10 December 2024 (10.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202311686000.7 11 December 2023 (11.12.2023) CN

(71) Applicant: **HANGZHOU DINOVA TE BIOTECH CO., LTD.**, [CN/CN]; Room 204, Building 2, No. 9 Juyuan Road, Xixing Street, Binjiang District, Hangzhou, Zhejiang 310051 (CN).

(72) Inventors: **ZHANG, Rui**; Room 1529, 15th Floor, Link Square, No. 222 Hubin Road, Huangpu District, Shanghai 200021 (CN). **WANG, Dongdong**; Room 1529, 15th Floor, Link Square, No. 222 Hubin Road, Huangpu District, Shanghai 200021 (CN). **LIU, Xinxing**; Room 1529, 15th Floor, Link Square, No. 222 Hubin Road, Huangpu District, Shanghai 200021 (CN). **ZHOU, Rui**; Room 2001, 2nd Floor, Unit 5, Building 7, No. 160 Basheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN). **TAN, Qingqiao**; Room 2001, 2nd Floor, Unit 5, Building 7, No. 160 Basheng Road, China (Shanghai) Pilot Free Trade Zone, Pudong New Area, Shanghai 200131 (CN).

(74) Agent: **JUN HE LAW OFFICES**; 20/F, China Resources Building 8 Jianguomenbei Avenue, Dongcheng District, Beijing 100005 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SIRNA MOLECULE FOR INHIBITING PCSK9 EXPRESSION AND USE THEREOF

(57) Abstract: Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.



WO 2025/124364 A1